GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Surrozen Inc (NAS:SRZN) » Definitions » Beneish M-Score

SRZN (Surrozen) Beneish M-Score : 4.04 (As of Mar. 14, 2025)


View and export this data going back to 2021. Start your Free Trial

What is Surrozen Beneish M-Score?

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Warning Sign:

Beneish M-Score 4.04 higher than -1.78, which implies that the company might have manipulated its financial results.

The historical rank and industry rank for Surrozen's Beneish M-Score or its related term are showing as below:

SRZN' s Beneish M-Score Range Over the Past 10 Years
Min: 4.04   Med: 4.04   Max: 4.04
Current: 4.04

During the past 4 years, the highest Beneish M-Score of Surrozen was 4.04. The lowest was 4.04. And the median was 4.04.


Surrozen Beneish M-Score Historical Data

The historical data trend for Surrozen's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Surrozen Beneish M-Score Chart

Surrozen Annual Data
Trend Dec20 Dec21 Dec22 Dec23
Beneish M-Score
- - - -

Surrozen Quarterly Data
Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - 4.04

Competitive Comparison of Surrozen's Beneish M-Score

For the Biotechnology subindustry, Surrozen's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Surrozen's Beneish M-Score Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Surrozen's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Surrozen's Beneish M-Score falls into.



Surrozen Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Surrozen for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 7.7073+0.528 * 1+0.404 * 1.4568+0.892 * 0.8+0.115 * 0.5927
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 1.0574+4.679 * 0.075086-0.327 * 0.8394
=4.04

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Sep24) TTM:Last Year (Sep23) TTM:
Total Receivables was $12.20 Mil.
Revenue was 10 + 0 + 0 + 0 = $10.00 Mil.
Gross Profit was 10 + 0 + 0 + 0 = $10.00 Mil.
Total Current Assets was $45.29 Mil.
Total Assets was $48.00 Mil.
Property, Plant and Equipment(Net PPE) was $1.67 Mil.
Depreciation, Depletion and Amortization(DDA) was $1.57 Mil.
Selling, General, & Admin. Expense(SGA) was $14.75 Mil.
Total Current Liabilities was $6.12 Mil.
Long-Term Debt & Capital Lease Obligation was $0.00 Mil.
Net Income was -1.434 + -25.261 + -8.83 + -8.913 = $-44.44 Mil.
Non Operating Income was -3.097 + -16.702 + -0.085 + 0.262 = $-19.62 Mil.
Cash Flow from Operations was -6.752 + -5.611 + -8.746 + -7.311 = $-28.42 Mil.
Total Receivables was $1.98 Mil.
Revenue was 0 + 0 + 0 + 12.5 = $12.50 Mil.
Gross Profit was 0 + 0 + 0 + 12.5 = $12.50 Mil.
Total Current Assets was $48.36 Mil.
Total Assets was $53.97 Mil.
Property, Plant and Equipment(Net PPE) was $4.81 Mil.
Depreciation, Depletion and Amortization(DDA) was $1.94 Mil.
Selling, General, & Admin. Expense(SGA) was $17.44 Mil.
Total Current Liabilities was $6.67 Mil.
Long-Term Debt & Capital Lease Obligation was $1.53 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(12.196 / 10) / (1.978 / 12.5)
=1.2196 / 0.15824
=7.7073

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(12.5 / 12.5) / (10 / 10)
=1 / 1
=1

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (45.286 + 1.673) / 47.998) / (1 - (48.357 + 4.814) / 53.973)
=0.021647 / 0.014859
=1.4568

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=10 / 12.5
=0.8

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(1.938 / (1.938 + 4.814)) / (1.571 / (1.571 + 1.673))
=0.287026 / 0.484279
=0.5927

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(14.754 / 10) / (17.441 / 12.5)
=1.4754 / 1.39528
=1.0574

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((0 + 6.12) / 47.998) / ((1.527 + 6.672) / 53.973)
=0.127505 / 0.151909
=0.8394

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(-44.438 - -19.622 - -28.42) / 47.998
=0.075086

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Surrozen has a M-score of 4.04 signals that the company is likely to be a manipulator.


Surrozen Beneish M-Score Related Terms

Thank you for viewing the detailed overview of Surrozen's Beneish M-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Surrozen Business Description

Traded in Other Exchanges
N/A
Address
171 Oyster Point Boulevard, Suite 400, South San Francisco, CA, USA, 94080
Surrozen Inc is a clinical-stage biotechnology company committed to discovering and developing drug candidates to selectively modulate the Wnt pathway, a critical mediator of tissue repair, in a broad range of organs and tissues. Its product candidate includes SZN-1326 (Fzd5/Lrp6, SWAP), SZN-413 and SZN-043 (E3/ASGR1, SWEETS).
Executives
Charles O Williams officer: Chief Financial Officer C/O HERITAGE FINANCIAL GROUP, 721 NORTH WESTOVER BOULEVARD, ALBANY GA 31707
Tim Kutzkey director, 10 percent owner 1700 OWENS STREET, SUITE 500, SAN FRANCISCO CA 94158
Column Group Iii Gp, Lp 10 percent owner 1700 OWENS STREET, SUITE 500, SAN FRANCISCO CA 94158
Anna Berkenblit director 830 WINTER STREET, WALTHAM MA 02451
Eric Bjerkholt director 132 PURDURE AVENUE, KENGSINGTON CA 94708
Blutt Mitchell J Md director, 10 percent owner 1370 AVENUE OF THE AMERICA, SUITE 3301, NEW YORK NY 10019
Christopher Y Chai director 2400 BAYSHORE PARKWAY, SUITE 200, MOUNTAIN VIEW CA 94043
Mary Haak-frendscho director 171 OYSTER POINT BLVD., SUITE 400, SOUTH SAN FRANCISCO CA 94080
Wen-chen Yeh officer: Chief Scientific Officer 171 OYSTER POINT BLVD., SUITE 400, SOUTH SAN FRANCISCO CA 94080
House Joshua Cory other: Former VP Business Development C/O CONSONANCE-HWF ACQUISITION CORP, 1 PALMER SQUARE, SUITE 305, PRINCETON NJ 08540
Geertrui Vanhove officer: Chief Medical Officer 1333 S. SPECTRUM BLVD #100, CHANDLER AZ 85286
Mace Rothenberg director 171 OYSTER POINT BLVD., SUITE 400, SOUTH SAN FRANCISCO CA 94080
Donald J Santel other: Former Director 4362 24TH STREET, SAN FRANCISCO CA 94114
David J Woodhouse director 630 GATEWAY BLVD., SOUTH SAN FRANCISCO CA 94080
Column Group Iii, Lp 10 percent owner 1700 OWENS STREET, SUITE 500, SAN FRANCISCO CA 94158